An independent panel of medical experts overwhelmingly said last week there is not enough evidence for the Food and Drug Administration to approve Biogen's experimental Alzheimer's drug, aducanumab.
Why it matters: This is one of the most consequential drug evaluations in years, aside from pending coronavirus vaccines and drugs. The FDA is not required to follow the experts' recommendations, but bucking their advice and siding with Biogen's data-parsing would call into question the agency's standards and motives.
